Search Results - "Lum, L. G."

Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: A pilot study by Lum, L G, Thakur, A, Pray, C, Kouttab, N, Abedi, M, Deol, A, Colaiace, W M, Rathore, R

“…A pilot phase I clinical trial involving 15 infusions of anti-CD3 × anti-CD20 bispecific Ab (CD20Bi)-armed anti-CD3-activated T cells (aATC) and low-dose IL-2…”
Get full text

Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML by Deol, A, Abrams, J, Masood, A, Al-Kadhimi, Z, Abidi, M H, Ayash, L, Lum, L G, Ratanatharathorn, V, Uberti, J P

“…We report the long-term follow up of 49 patients (pts) enrolled on plerixafor compassionate use protocol. Thirty-seven pts (76%) had failed one previous…”
Get full text

Large pericardial effusion as a complication in adults undergoing SCT by Norkin, M, Ratanatharathorn, V, Ayash, L, Abidi, M H, Al-Kadhimi, Z, Lum, L G, Uberti, J P

“…Large pericardial effusion (LPE) leading to cardiac tamponade is a rare complication described in patients undergoing SCT. This complication is considered to…”
Get full text

Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention by Al-Kadhimi, Z, Gul, Z, Abidi, M, Lum, L G, Deol, A, Chen, W, Jang, H, Ozust, C, Langston, A, Waller, E, Uberti, J

“…Chronic GvHD (cGvHD) is the leading cause of late non-relapse mortality (NRM) and morbidity after allogeneic hematopoietic stem cell transplant (AHSCT). We…”
Get full text

Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT by Ratanatharathorn, V, Deol, A, Ayash, L, Cronin, S, Bhutani, D, Lum, L G, Abidi, M, Ventimiglia, M, Mellert, K, Uberti, J P

“…We performed a retrospective analysis of the outcome of 197 consecutive unrelated donor transplant recipients who received GVHD prophylaxis either TM regimen…”
Get full text

The Kinetics of Immune Reconstitution After Human Marrow Transplantation by Lum, Lawrence G.

“…Human marrow transplantation for the treatment of malignant and nonmalignant disorders is becoming an established modality of therapy. As in any aggressive…”
Get full text

Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma by VORAVIT RATANATHARATHORN, UBERTI, J, KARANES, C, ABELLA, E, LUM, L. G, MOMIN, F, CUMMINGS, G, SENSENBRENNER, L. L

“…A prospective comparative trial of allogeneic versus autologous bone marrow transplant (BMT) was conducted. Sixty-six consecutive patients (median age, 41;…”
Get full text

Triple MEL100 Therapy in Multiple Myeloma by Berz, D, Colvin, G.A, McCormack, E.M, Winer, E.S, Karwan, P, Colvin, L, Rathore, R, Lum, L.G, Elfenbein, G.J, Quesenberry, P.J

“…Abstract Background Tandem high-dose melphalan therapy with autologous peripheral stem cell support has emerged as the standard of care for patients without…”
Get full text

Low blood lymphocyte count at 30 days post transplant predicts worse acute GVHD and survival but not relapse in a large retrospective cohort by Gul, Z, Van Meter, E, Abidi, M, Ditah, I, Abdul-Hussein, M, Deol, A, Ayash, L, Lum, L G, Waller, E K, Ratanatharathorn, V, Uberti, J, Al-Kadhimi, Z

“…Multiple reports have shown that low absolute lymphocyte count at day 30 (ALC30) after allogeneic hematopoietic SCT (AHSCT) is associated with higher risk of…”
Get full text

T cell-based immunotherapy for cancer: a virtual reality? by Lum, L. G

“…The goal of harnessing the immune system to recognize tumor as "nonself" is not new. Now, thanks to new knowledge and new techniques, however, modalities that…”
Get full text

The marrow stem cell: the continuum by Quesenberry, P J, Colvin, G A, Abedi, M, Lambert, J F, Moore, B, Demers, D, Greer, D, McAuliffe, C, Dooner, M, Lum, L G, Badiavas, E, Falanga, V

“…The marrow hematopoietic stem cell is currently being redefined as to all aspects of its phenotype and its total differentiation capacity. This redefinition…”
Get full text

T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer by Garlie, N K, LeFever, A V, Siebenlist, R E, Levine, B L, June, C H, Lum, L G

“…This report describes the generation of T cells with characteristics that may prove useful for the immunotherapy of cancer. Peripheral blood mononuclear cells…”
Get more information

T cell activation modulates retrovirus-mediated gene expression by Quinn, E R, Lum, L G, Trevor, K T

“…Important considerations for T lymphocyte-based gene therapy include efficient gene delivery and expression in primary, human T cells. In this study,…”
Get more information

Immune recovery after bone marrow transplantation by Lum, L G

“…The donor-derived immune system that forms after bone marrow transplantation (BMT) takes as long as 2 years to develop in healthy BMT recipients. Soon after…”
Get more information

Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia by Loughran, Jr, T P, Kadin, M E, Starkebaum, G, Abkowitz, J L, Clark, E A, Disteche, C, Lum, L G, Slichter, S J

“…Three patients had leukocytosis of large granular lymphocytes and chronic neutropenia. Clonal chromosomal abnormalities (trisomy 8 and trisomy 14) and…”
Get more information

Effect of disruption of Akt-1 of lin−c-kit+ stem cells on myocardial performance in infarcted heart by Tseng, Andy, Stabila, Joan, McGonnigal, Beth, Yano, Naohiro, Yang, Mao-Jing, Tseng, Yi-Tang, Davol, Pamela A., Lum, Lawrence G., Padbury, James F., Zhao, Ting C.

“…Aims We have demonstrated an important role of bone marrow-derived stem cells in preservation of myocardial function. We investigated whether Akt-1 of…”
Get full text

Activated T-cell and bispecific antibody immunotherapy for high-risk breast cancer. Bench to bedside by Lum, L G, Sen, M

“…Nontoxic approaches are needed to improve overall survival (OS) and progression-free survival (PFS) for high-risk breast cancer. Combination immunotherapy (IT)…”
Get more information

Phase I study of alpha-interferon augmentation of cyclosporine-induced graft versus host disease in recipients of autologous bone marrow transplantation by Ratanatharathorn, V, Uberti, J, Karanes, C, Lum, L G, Abella, E, Dan, M E, Hussein, M, Sensenbrenner, L L

“…To explore the augmentation of cyclosporin-induced graft-versus-host disease (GVHD) in autologous bone marrow transplantation (BMT), we conducted a phase I…”
Get more information

Transfer of allergen-specific IgE-mediated hypersensitivity with allogeneic bone marrow transplantation by Agosti, J M, Sprenger, J D, Lum, L G, Witherspoon, R P, Fisher, L D, Storb, R, Henderson, Jr, W R

“…We investigated whether allergen-specific IgE-mediated hypersensitivity is transferred by bone marrow transplantation. Twelve patients, 14 to 47 years of age,…”
Get more information

Autoimmune thyroiditis after bone marrow transplantation by Wyatt, D T, Lum, L G, Casper, J, Hunter, J, Camitta, B

“…We describe the transfer of autoimmune thyroiditis by bone marrow transplantation. The male recipient developed compensated hypothyroidism 3 years after…”
Get more information